Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States

Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States

Background: The management of muscle-invasive bladder cancer (MIBC) remains challenging. The phase III NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy significantly enhances event-free and overall survival for MIBC patients. However, due to the high cost of durvalumab, assess...

Full description

Saved in:
Bibliographic Details
Main Authors: Caicong You, Jiahao Zhang, Jianying Lei, Wu Fu, Maobai Liu, Hongfu Cai, Bin Zheng, Na Li
Format: Article
Language:English
Published: SAGE Publishing 2025-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251357519
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items